Pharmacologic inhibition of cyclin-dependent kinases 4 and 6 arrests the growth of glioblastoma multiforme intracranial xenografts.
暂无分享,去创建一个
M. Prados | C. James | E. Oermann | T. Waldman | T. Ozawa | D. Solomon | Jung‐Sik Kim | W. Zhong | K. Michaud | C. James | W. Zhong
[1] K. Flaherty,et al. Treatment of growing teratoma syndrome. , 2009, The New England journal of medicine.
[2] M. J. van den Bent,et al. Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma , 2009, British Journal of Cancer.
[3] J. Dering,et al. PD 0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially inhibits proliferation of luminal estrogen receptor-positive human breast cancer cell lines in vitro , 2009, Breast Cancer Research.
[4] Nicholas J. Wang,et al. Comparative analyses of gene copy number and mRNA expression in glioblastoma multiforme tumors and xenografts. , 2009, Neuro-oncology.
[5] Habtom W Ressom,et al. Sample type bias in the analysis of cancer genomes. , 2009, Cancer research.
[6] A. Giordano,et al. Cell cycle kinases as therapeutic targets for cancer , 2009, Nature Reviews Drug Discovery.
[7] J. Villano,et al. Temozolomide in malignant gliomas: current use and future targets , 2009, Cancer Chemotherapy and Pharmacology.
[8] M. Barbacid,et al. Cell cycle, CDKs and cancer: a changing paradigm , 2009, Nature Reviews Cancer.
[9] K. Anderes,et al. Advancing Bioluminescence Imaging Technology for the Evaluation of Anticancer Agents in the MDA-MB-435-HAL-Luc Mammary Fat Pad and Subrenal Capsule Tumor Models , 2009, Clinical Cancer Research.
[10] T. Ryken,et al. Mutational inactivation of PTPRD in glioblastoma multiforme and malignant melanoma. , 2008, Cancer research.
[11] S. Chen‐Kiang,et al. A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model. , 2008, Cancer research.
[12] Hai Yan,et al. Identification of p18 INK4c as a tumor suppressor gene in glioblastoma multiforme. , 2008, Cancer research.
[13] Webster K. Cavenee,et al. Feedback Circuit among INK4 Tumor Suppressors Constrains Human Glioblastoma Development , 2008, Cancer cell.
[14] M. Mehta,et al. Radiotherapy and radiosensitizers in the treatment of glioblastoma multiforme. , 2007, Clinical advances in hematology & oncology : H&O.
[15] C. James,et al. Identification of molecular characteristics correlated with glioblastoma sensitivity to EGFR kinase inhibition through use of an intracranial xenograft test panel , 2007, Molecular Cancer Therapeutics.
[16] S. Ely,et al. A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6. , 2006, Cancer research.
[17] Koji Yoshimoto,et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. , 2005, The New England journal of medicine.
[18] Kevin Camphausen,et al. Influence of in vivo growth on human glioma cell line gene expression: convergent profiles under orthotopic conditions. , 2005, Proceedings of the National Academy of Sciences of the United States of America.
[19] C. James,et al. Patient tumor EGFR and PDGFRA gene amplifications retained in an invasive intracranial xenograft model of glioblastoma multiforme. , 2005, Neuro-oncology.
[20] D. W. Fry,et al. Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. , 2005, Journal of medicinal chemistry.
[21] N. Pryer,et al. Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. , 2004, Molecular cancer therapeutics.
[22] Douglas C. Miller,et al. Flavopiridol induces apoptosis in glioma cell lines independent of retinoblastoma and p53 tumor suppressor pathway alterations by a caspase-independent pathway. , 2003, Molecular cancer therapeutics.
[23] A. Merlo,et al. Frequent Co‐Alterations of TP53, p16/CDKN2A, p14ARF, PTEN Tumor Suppressor Genes in Human Glioma Cell Lines. , 1999, Brain pathology.
[24] D. Louis,et al. Molecular Genetic Correlates of p16, cdk4, and pRb Immunohistochemistry in Glioblastomas , 1998, Journal of neuropathology and experimental neurology.
[25] V P Collins,et al. Human glioblastomas with no alterations of the CDKN2A (p16INK4A, MTS1) and CDK4 genes have frequent mutations of the retinoblastoma gene. , 1996, Oncogene.
[26] J. Olson,et al. Lack of p16INK4 or retinoblastoma protein (pRb), or amplification-associated overexpression of cdk4 is observed in distinct subsets of malignant glial tumors and cell lines. , 1995, Cancer research.
[27] K. Kinzler,et al. Deletion of p16 and p15 genes in brain tumors. , 1994, Cancer research.
[28] C. James,et al. CDK4 amplification is an alternative mechanism to p16 gene homozygous deletion in glioma cell lines. , 1994, Cancer research.
[29] P. Humphrey,et al. Characterization of the epidermal growth factor receptor in human glioma cell lines and xenografts. , 1990, Cancer research.
[30] J. Uhm. Comprehensive genomic characterization defines human glioblastoma genes and core pathways , 2009 .
[31] J. Uhm. An Integrated Genomic Analysis of Human Glioblastoma Multiforme , 2009 .
[32] D. Louis,et al. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated. , 1996, Cancer research.